-
InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
•
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a clinical study for its B-cell lymphoma-2 (BCL2) inhibitor ICP-248. The study, approved in China in September last year, marks a significant step in the development of this novel therapy. Drug Profile and IndicationsICP-248 is a…
-
Thederma Pharmaceuticals Raises RMB 100 Million for AhR-Targeted Therapies
•
China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million) in a Series A financing round. The round was led by Bainuo Capital, with participation from existing investor Hankang Capital. The proceeds will be used to support research and development and clinical studies for multiple…
-
Xinrui Medtech Secures Pre-Series A Funding for Cardiovascular Device Development
•
Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. The round was led by HM Capital, with a contribution from Northern Lights Venture Capital. The proceeds will be used to support clinical studies, new product research…
-
Lifetech Scientific’s IBS Angel Stent Receives CE MDR Certification in EU
•
China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification in the European Union (EU) for its in-house developed IBS Angel iron-based absorbable stent system. This marks the world’s first commercialization of such a product in the EU. The first-in-class product is designed for minimally…
-
Olipharma Raises Funds in Pre-Series A+ Round to Expand Manufacturing Facilities
•
Olipharma, a small nucleic acid drug Contract Development and Manufacturing Organization (CDMO) based in Suzhou, has reportedly raised an undisclosed amount of money in a Pre-Series A+ financing round. The investment was led by Tsing Song Capital and Addor Capital, with participation from existing investor Matrix Partners. The proceeds will…
-
Inventiva and Chia Tai Tianqing File Clinical Trial for Lanifibranor with CDE
•
France-based Inventiva S.A. and China’s Chia Tai Tianqing have filed a clinical trial application with the Center for Drug Evaluation (CDE) for their Category 1 drug, lanifibranor. The application has been accepted for review. Lanifibranor is an oral peroxisome proliferator-activated receptor (PPAR) agonist designed to treat non-alcoholic fatty liver disease…
-
Simcere Pharmaceutical Initiates Clinical Study for Bispecific Antibody SIM0237 in Advanced Tumors
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical study for its bispecific antibody (BsAb) SIM0237, targeting PD-L1 and IL-15 in advanced solid tumors. The global multi-center, open-label Phase I study is designed to assess the safety, efficacy, and pharmacokinetics/pharmacodynamics of the drug. The…
-
AusperBio and Asymchem Form Strategic Partnership for New Drug R&D and Services
•
China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership to enhance their collaboration in new drug R&D technical services, drug administration and regulation consultation, brand linkage communication, and more. This partnership builds on their existing collaboration, which has already yielded significant results in the…
